Volume 11, Number 3 (Apr 2020)

Editorial

JADPRO Live 2019: Practice Innovation

In this special issue to JADPRO, we showcase select educational sessions from our annual meeting.  

Meeting Report

Precision Oncology Comes of Age: Tumor-Agnostic Approaches

Colleen Lewis, MSN, ANP-BC, AOCNP®, and R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, presented on the new world of tumor-agnostic treatment approaches, including those aimed at managing patients with tumors that have high microsatellite ...

April 21, 2020

Meeting Report

Immune Checkpoint Inhibitor–Based Therapy as a Backbone in Cancer Treatment

At JADPRO Live 2019, Krista M. Rubin, MS, FNP-BC, and Anthony J. Olszanski, MD, RPh, reviewed the basic concepts of immunotherapy and the current treatment landscape, and discussed emerging data for immune checkpoint inhibitor–based comb...

April 21, 2020

Meeting Report

Biomarker BINGO

This JADPRO Live session tested attendees’ knowledge on biomarkers and their use in determining targeted therapy for certain tumor types, key assays used to measure common biomarkers, and guideline-endorsed biomarker testing recommendati...

April 20, 2020

Meeting Report

Adoptive Cell Therapies: Keeping Pace With New and Emerging Advances

At JADPRO Live 2019, Patricia Mangan, RN, MSN, CRNP, and Edward Stadtmauer, MD, discussed the emerging world of chimeric antigen receptor (CAR) T-cell therapy, including the CAR T-cell process, approved indications and studies in hematol...

April 20, 2020

Meeting Report

Challenges of Integrating Biosimilars Into Clinical Practice

Presenters at JADPRO Live 2019 discussed the chemical and clinical nature of biosimilars, reviewed biosimilar development in oncology, and discussed implementation strategies for biosimilars. 

April 20, 2020

Meeting Report

2018–2019 Drug Updates in Hematologic Malignancies

Lauren Held, PharmD, BCOP, updated attendees on the FDA-approved therapies for initial or expanded indications for hematologic malignancies across the past year, as well as their supporting clinical trial data and best practices for safe...

April 20, 2020

Meeting Report

2018–2019 Drug Updates in Solid Tumors

Sally Barbour, PharmD, BCOP, CPP, FHOPA, updated attendees on the FDA-approved therapies for initial or expanded indications for solid tumors across the past year, as well as their supporting clinical trial data and best practices for sa...

April 20, 2020

Meeting Report

First-Line Therapy for Metastatic Non–Small Cell Lung Cancer: State-of-the-Art Targeted Therapy and Immunotherapy Approaches

At JADPRO Live 2019, Joshua Bauml, MD, and Christina Knepley, CRNP, discussed how to devise treatment plans for patients with metastatic non–small cell lung cancer, including using biomarkers to guide treatment selection, understanding c...

April 21, 2020

Meeting Report

Expert Insights on Triple-Negative Breast Cancer: Preparing for the Next Wave of Treatments

Heather R. Greene, MSN, FNP, AOCNP®, and Lee S. Schwartzberg, MD, FACP, discussed the current and future treatment landscape for triple-negative breast cancer, including recent and emerging data on approved treatments, novel therapeutic ...

April 21, 2020

Meeting Report

Improving Outcomes in HER2-Positive Breast Cancer: Analysis and Application of Evolving Data and Best Practices

Through expert, case-based discussion, Jame Abraham, MD, and Kelley Mayden, MSN, FNP, AOCNP®, presented existing and emerging data for current and investigational therapies for HER2-positive breast cancer and their associated adverse eve...

April 21, 2020

Meeting Report

Hormone Receptor–Positive, HER2-Negative Breast Cancer: Recent Advances and Best Practices

Lee Schwartzberg, MD, FACP, and Heather Greene, MSN, FNP, AOCNP®, reviewed optimal therapy for patients with hormone receptor–positive, HER2-negative breast cancer, as well as the management of adverse events associated with treatment. 

April 21, 2020

Meeting Report

Creating Clarity in Metastatic Melanoma: Optimizing Treatment and Improving Outcomes

Checkpoint inhibitors and oncolytic vaccine therapy have transformed the management of metastatic melanoma. This article presents the diagnosis and treatment landscape for metastatic melanoma, including clinicopathologic features of the ...

April 21, 2020

Meeting Report

Improving Outcomes for Patients With Advanced Urothelial Carcinoma

At JADPRO Live 2019, Petros Grivas, MD, PhD, and Jeannette Hammond, PA-C, reviewed data regarding mechanistic activity, efficacy, and safety of approved and emerging therapies for advanced or metastatic urothelial carcinoma, the selectio...

April 21, 2020

Meeting Report

Improving Outcomes for Patients With Metastatic Colorectal Cancer: Challenges and Strategies

At JADPRO Live 2019, Leslie A. Swanson, ARNP, and Kathleen Boyle,PA-C, reviewed guideline-concordant molecular testing and therapy in patients with metastatic colorectal cancer (mCRC), the clinical significance of emerging data for exist...

April 20, 2020

Meeting Report

Current and Future Directions for PARP Inhibition

Megan Grudem, APRN, CNP, and Andrea Wahner Hendrickson, MD, reviewed the potential role of PARP inhibition in various malignancies, how to select patients who are appropriate candidates, and guidance on devising treatment plans that incl...

April 21, 2020

Meeting Report

Recent Advances in the Treatment Of Newly Diagnosed Multiple Myeloma

Edward Libby, MD, and Josh Epworth, ARNP, interpreted data on current and novel treatments, discussed how to select initial therapy based on patient risk and in alignment with guidelines and best practices, and evaluated the use of minim...

April 21, 2020

Meeting Report

Integrating Best Practices to Improve Outcomes in Relapsed/Refractory Multiple Myeloma

Amy E. Pierre, MSN, ANP-BC, and Joshua Richter, MD, break down the approved and emerging treatment options for relapsed/refractory multiple myeloma, including mechanisms of action, supporting clinical data, and associated adverse events,...

April 21, 2020

Meeting Report

Improving Outcomes for Patients With Chronic Lymphocytic Leukemia

Mazyar Shadman, MD, MPH, and Amy Goodrich, CRNP, reviewed data regarding the mechanistic activity, efficacy, and safety of approved and emerging therapeutic options for chronic lymphocytic leukemia (CLL) and strategies for managing adver...

April 20, 2020

Meeting Report

Addressing the Challenges of Aggressive Lymphomas

Katherine L. Byar, MSN, ANP-BC, BMTCN®, and Matthew Lunning, DO, FACP, covered how to tackle challenges in the treatment of aggressive lymphomas by understanding how to apply emerging data, reviewing optimal therapies and treatment recom...

April 20, 2020